Advanced Cancer Pain Management Market to Grow Positively at a Paltry CAGR During the Study Period (2019-2032), Assesses DelveInsight | Companies- Tetra Bio-Pharma, WEX Pharmaceuticals, Sorrento Therapeutics, and others

United States, Nevada, Las Vegas, DelveInsight's "Advanced Cancer Pain Management - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Advanced Cancer Pain Management market share of the individual therapies, current and forecasted Advanced Cancer Pain Management market size from 2019 to 2032 segmented by seven major markets. The report also offers current Advanced Cancer Pain Management therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Advanced Cancer Pain Management market.
Download sample report @ https://www.delveinsight.com/report-store/advanced-cancer-pain-management-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Advanced Cancer Pain Management Overview
Pain is a common occurrence in cancer patients, especially when the disease reaches an advanced stage, with estimates suggesting that it affects over 70% of these individuals. This pain significantly impacts their overall physical and emotional well-being.

The pain experienced by cancer patients can be attributed to several factors. Firstly, it can be a direct result of the damage caused by tumors, which may destroy or apply pressure to surrounding tissues, bones, or nerves. Additionally, tumors can obstruct hollow body structures like the digestive system, blood vessels, and lymph vessels, further exacerbating pain.

Furthermore, cancer treatments themselves can lead to pain. Surgical procedures are the most common cause, but chemotherapy, immunotherapy, and radiation therapy can also induce pain in some cases.

The National Institutes of Health report varying rates of pain prevalence depending on the stage of cancer and treatment. Pain is reported in 39.3% of patients after curative treatment, 55.0% during anticancer treatment, and 66.4% in advanced, metastatic, or terminal disease stages.

Mild and moderate pain in cancer patients often manifests as muscle pain, bone pain, or discomfort resulting from surgical incisions. Relief for such pain can be achieved through the use of non-opioid medications like acetaminophen (Tylenol) and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen (Advil). These non-opioid pain relievers are typically prescribed alongside opioids and other therapies to provide more effective pain relief.

In cases of moderate to severe pain, opioids are highly effective medications for managing cancer-related pain. These opioids include drugs like morphine, fentanyl, codeine, oxycodone, hydromorphone, and methadone. There is sometimes concern about the potency of morphine, but opioids can be combined with non-opioid drugs like acetaminophen or NSAIDs to manage moderate pain. For severe pain, opioids can be used in conjunction with other medications and therapies.

Breakthrough cancer pain (BTcP) is characterized by sudden, intense, and brief pain episodes that occur on top of a stable baseline of pain control in cancer patients. BTcP significantly impairs patients' quality of life and their ability to carry out everyday tasks. The standard treatment for BTcP involves the use of fast-acting opioids and immediate-release oral opioids, such as morphine sulfate, hydromorphone, and oxycodone.

Request for a sample report @ https://www.delveinsight.com/report-store/advanced-cancer-pain-management-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Advanced Cancer Pain Management Epidemiological Insights
In a study by Jiang et al. (2019), of the identified 4526 cancer survivors, 1648 reported having chronic pain and 768 reported having HICP, representing approximately 5.39 million and 2.51 million cancer survivors, respectively, in the US population.
In a study by Everdingen et al. (2016), pain prevalence rates were 39.3% after curative treatment; 55.0% during anticancer treatment; and 66.4% in advanced, metastatic, or terminal disease. Moderate to severe pain was reported by 38.0% of all patients.
In a study by Marieke et al. (2016), pain severity resulted in a 38.0% prevalence of moderate to severe pain. With reference to types of cancer, lower pain prevalence rates were demonstrated in prostate cancer compared to head and neck, lung, and breast cancer.
In a study by Rustøen et al. (2013), high intensity of breakthrough cancer pain was described by 75.5% of the patients, and the painful crises can be exacerbated by either predictable or unpredictable events.
Advanced Cancer Pain Management Treatment Market
The World Health Organization (WHO) analgesic ladder for the treatment of cancer pain provides a three-step sequential approach for analgesic administration based on pain severity that has global applicability. Non-opioids are recommended for mild pain, with the addition of mild opioids for moderate pain and strong opioids for severe pain. The World Health Organization (WHO) analgesic ladder for the treatment of cancer pain provides a three-step sequential approach for analgesic administration based on pain severity that has global applicability. Non-opioids are recommended for mild pain, with the addition of mild opioids for moderate pain and strong opioids for severe pain.
Promising Therapies in the Advanced Cancer Pain Management Pipeline
QIXLEEF
Halneuron
RTX
And others
Discover more about Advanced Cancer Pain Management therapies in the pipeline @ https://www.delveinsight.com/sample-request/advanced-cancer-pain-management-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Advanced Cancer Pain Management Market
Tetra Bio-Pharma
WEX Pharmaceuticals
Sorrento Therapeutics
And others
To understand key companies related to the Advanced Cancer Pain Management Market, get a snapshot of the Advanced Cancer Pain Management Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/advanced-cancer-pain-management-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Advanced Cancer Pain Management Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Advanced Cancer Pain Management Companies: Tetra Bio-Pharma, WEX Pharmaceuticals, Sorrento Therapeutics, and others
Key Advanced Cancer Pain Management Pipeline Therapies: QIXLEEF, Halneuron, RTX, and others
Therapeutic Assessment: Advanced Cancer Pain Management current marketed and emerging therapies
Advanced Cancer Pain Management Market Dynamics: Advanced Cancer Pain Management market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Advanced Cancer Pain Management Market Access and Reimbursement
Table of Contents
1. Advanced Cancer Pain Management Market Key Insights
2. Advanced Cancer Pain Management Market Report Introduction
3. Advanced Cancer Pain Management Market Overview at a Glance
4. Advanced Cancer Pain Management Market Executive Summary
5. Disease Background and Overview
6. Advanced Cancer Pain Management Treatment and Management
7. Advanced Cancer Pain Management Epidemiology and Patient Population
8. Patient Journey
9. Advanced Cancer Pain Management Emerging Drugs
10. 7MM Advanced Cancer Pain Management Market Analysis
11. Advanced Cancer Pain Management Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Advanced Cancer Pain Management Market Drivers
15. Advanced Cancer Pain Management Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.